Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer; Breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 14 Nov 2016 According to a Puma Biotechnology media release, trial design of this trial will be presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
- 28 Oct 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2018.